apgwgzminoxidil2%

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
apgwgzminoxidil2%
Generic name
MINOXIDIL
Manufacturer
Guangdong Jiaoyu Biotechnology Co., Ltd
Product type
HUMAN OTC DRUG
SPL set ID
5957c990-e274-6278-e063-6394a90af2b7
SPL ID
5957c949-5dc2-956f-e063-6294a90ac22b
Version
1
Effective date
2026-08-18
Source export date
2026-09-28
Source partition
8
Source file
https://download.open.fda.gov/drug/label/drug-label-0008-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-09-28/ae3816359e336a5de4f44607730a3d12ceb61ffa012a132189ceda22541b38ee/drug-label-0008-of-0014.json.zip
Source manifest SHA-256
cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
Import run
20260929T050834Z
Imported at
2026-09-29 05:56:16
Harmonized routes table
Harmonized routes
TOPICAL

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings

For external use only. Do not use if your hair loss is sudden, patchy, or the cause is unknown; you are under 18 years of age; your scalp is red, inflamed, infected, irritated, or painful; or you use other medicines or treatments on the scalp. Ask a doctor before use if you have heart disease. When using this product, apply only to the scalp and avoid contact with eyes. Unwanted facial hair growth may occur. Changes in hair color or texture may occur. It may take 2–4 months to see results, and results vary by individual. Stop use and ask a doctor if chest pain, rapid heartbeat, dizziness, or fainting occurs; sudden weight gain or swelling occurs; severe scalp irritation occurs; or no hair growth occurs after 4 months of use.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.